J.M. Carrascosa

Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study

Satveer K. Mahil, Nick Dand, K.J. Mason et al. · Journal of Allergy and Clinical Immunology · 2020 · 158 citations · Full text

Adverse Covid-19 Outcomes, Global Health, Covid-19 Pandemic +9

Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry

P. Dávila‐Seijo, E. Daudén, M.Á. Descalzo et al. · Journal of Investigative Dermatology · 2016 · 123 citations · Full text

Classic Systemic Drugs, Psoriatic Arthritis, Clinical Dermatology +6

Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting

R. Navarro Suay, Eva Vilarrasa, Pedro Herranz et al. · British Journal of Dermatology · 2012 · 99 citations

Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study

Tiago Torres, L. Puig, Ronald Vender et al. · American Journal of Clinical Dermatology · 2022 · 73 citations · Full text

Inflammation, Drug Survival, Immunology +7

Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5‐year observational study of clinical practice: 2008–2013 results of the Biobadaderm registry

G. Carretero, E. Daudén, Francisco Vanaclocha Sebastián et al. · Journal of the European Academy of Dermatology and Venereology · 2014 · 65 citations · Full text